Marvel Biosciences Corp.’s Post

Phototermal therapy (PTT) is receiving attraction as a promising imaging-guided therapy modality against cancer with its high efficiency, precise localization, and, most importantly, minimal invasiveness to normal tissues. Yet, this novel strategy still requires methods to overcome the limitations in stability as well as targeting efficiency. In order to tackle these challenges, a group of researchers came up with a well-structured strategy utilizing EVs. The idea in this study is to engineer EVs with E8 nanobody against CDH17, a well-known marker for gastrointestinal cancers, and load them with croconaine (CR) dyes for energy transfer in a biocompatible and biodegradable way with low toxicity. Utilizing such modified EVs in tumor-bearing mice demonstrated that these bio-nanocomposites not only possess high tumor-targeting capability, but also are highly photostable and biocompatible, two critical features for therapeutic applications. This way, the approach holds great promise for future clinical translation. If you are interested in further reading: https://lnkd.in/duFCE6J6 #extracellularvesicles #exosomes #EVs #nanobodies #phototermaltherapy #cancertherapeutics

To accelerate the development of the next generation of advanced cancer therapies, we can use multi-omics approaches to better understand the disease and identify the most appropriate therapeutic targets.    In our article, showcased at #AACR and published in April’s Cancer Discovery, my AstraZeneca colleagues @Richard Goodwin @Jorge Reis-Filho, @Simon Barry and I discuss the deployment of platforms that generate increasingly complex data, and consider how to translate these into practical and scalable applications.    Read the article here: https://lnkd.in/efh_g7EB   #Spatialomics #PrecisionMedicine #Multiomics 

Excited to announce Dr. Zhinan Xia, CEO & Founder of Abimmune Biotherapeutics, presenting at our Alcor Drug Discovery Platform in New Jersey's Crown Plaza! Topic: Unveiling our Novel ADC Platform Dr. Zhinan Xia, a trailblazer in molecular immunology and oncology, brings a wealth of expertise to the table. Armed with a Ph.D. from the University of Kentucky and postdoctoral training at Harvard Medical School, Dr. Xia spearheads Abimmune Biotherapeutics LLC as its Founder and President. His groundbreaking research revolves around the expression of an active form of human granzyme B, crucial for T cell-mediated killing of tumors and virally infected cells. His focus on immunotherapy for cancer and immune-related rare diseases is reshaping the landscape of Kendall Square, Cambridge, MA. Join us as Dr. Xia shares insights into our innovative ADC platform, promising advancements in the fight against cancer and beyond. Don't miss out on this opportunity to delve into the future of biotechnology with a visionary leader! #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits  #DrugDiscoverySummits #EuropeanClinicalTrialSummits #Scientist #DrugDiscovery #Preclinical #Medchem #Biology #Protein #Antibodies #Conference #InPersonEvent #Summit #AI #ML #Data #Oncology #DrugDevelopment #Collaboration #Keynote #PanelDiscussion #Oncology #Therapeutics #DrugDesign #SmallMolecules #LargeMolecules #Events #Therapeutics #BigData #Marketing #DigitalMarketing #AIdrug #alcordrug #alcordiscovery #addp2024

Discover how 3D whole-brain light sheet imaging can be instrumental in preclinical target and drug discovery. Come speak to Gubra's scientists at our two posters on Oct. 9 (8am-12pm) at #SfN2024: - Brain delivery and efficacy of a BBB shuttle-enhanced aducanumab biosimilar in a mouse model of Alzheimer’s disease (poster B132) - Quantitative 3D imaging of orexin and orexin receptor distribution in the intact mouse brain (poster B24)

📢 Will we see you at the STING & TLR-Targeted Therapies Summit next week? 📢 We will be present at the 5th edition of the conference on June 19-20, 2024, in San Diego, CA. On Wednesday, June 19, at 1 p.m. PDT, Kader Thiam, our Senior Vice President - Discovery, Preclinical Models and Services, will give a presentation titled "Profiling STING and TLR-Targeted Therapies in Preclinical Models" 🔬 The presentation will focus on: ▶ STING humanized models and #BRGSF-HIS, a hCD34+ reconstituted mice featuring human lymphoid and myeloid compartments ▶ Characterization of the immune responses ▶ Assessment of STING and TLR-targeting agents in these models If you are also attending the summit, let’s connect and explore new opportunities for collaboration. Learn more about our BRGSF-HIS mouse here 👉 https://lnkd.in/e5hpc3_G Read more on our humanized STING mouse here 👉 https://lnkd.in/eTUNM38D Get more information on the summit here 👉 https://lnkd.in/efnTJBA #stingmodel #preclinicalmodels #cancerresearch

Do you have a research problem that could benefit from 5 days of dedicated time from researchers with computational modelling expertise? We are now accepting challenge ideas from Industry and Clinicians for our mathematical study group being held next April at The University of Nottingham in collaboration with the UK Quantitative Systems Pharmacology Network. Innovate UK Business Connect We welcome challenges in areas that include respiratory infectious diseases, respiratory cancer, respiratory therapeutics, etc. Find out more: bit.ly/SG_2025 We look forward to working with you! #mathematics #modelling #studygroup #respiratory #medicine #computerscience #pharmacology

I am thrilled to announce the publication of my PhD paper, "CD206+ Macrophages Are Relevant Non-Invasive Imaging Biomarkers and Therapeutic Targets in Experimental Lung Fibrosis" in #ThoraxBMJ journal 🔸 The imaging of CD206 appears as a relevant target in #pulmonaryfibrosis 🔸 The JAKinib tofacitinib, reduces bleomycin-induced lung fibrosis by reducing the pool of CD206-expressing macrophages, and turns out to be a promising treatment to #cureIPF 🔸 CD206-targeted imaging with the radiopharmaceutical 99mTc-tilmanocept represents a non-invasive imaging tool able to monitor nintedanib and tofacitinib efficacy 🔥 CD206 imaging by 99mTc-tilmanocept reprensents an outstanding tool to select patients with high CD206+ cell infilftration in the lungs to lead them with an anti-CD206 therapy, including the new potent drug tofacitinib, but can also be used to assess the efficacy of existing antifibrotic treatment such as nintedanib 🔥 #Lungfibrosis #Respiratoryresearch #ThoraxBMJ This work could not have been done without Pierre-Simon Bellaye CGFL - Centre Georges-François Leclerc and my supervisor Philippe Bonniaud and Francoise Goirand CHU Dijon Bourgogne UBFC - Université Bourgogne-Franche-Comté. Additional acknowledgments to Olivier Burgy, Carmen Garrido, Lucile Dondaine Nicolas Pernet ImaFlow, and Guillaume Beltramo. Read us here: https://lnkd.in/eGgjxv4y

At AstraZeneca we are using the power of multi-omics to gain novel insights into the molecular changes that underpin cancer and response to treatment.   Together with my colleagues (Stefan Platz, Jorge Reis-Filho & Simon Barry), I’m delighted to share an article published in Cancer Discovery, and showcased at #AACR, in which we discuss how spatial-omics platforms and data can be used to inform the development of the next generation of therapeutics.   This highlights the complexity of data analytics and why it’s important that researchers find ways to harmonise approaches.   A big thank you and congratulations to all involved.   You can find the article here: https://lnkd.in/eGsjxiFV #Spatialomics #Multiomics #ArtificialIntelligence

📣 Our focus is on OATD-01 and its breakthrough therapy potential, and progress of OATD-02 trial in patients with solid tumors, which led to reduction of programs in the discovery from five to three.  Key areas for further development and value building for #Molecure are: #OATD01 as a potential breakthrough therapy for the treatment of sarcoidosis and MASH, and #OATD02 in trials in patients with solid tumors. Development of projects in the discovery phase powered by machine learning and generative artificial intelligence (GenAI) methods includes a small-molecule drug discovery platform that modulates #mRNA translational function and the USP7 program. ➡️ For more information click here: https://lnkd.in/ekeFW-QY

Proud of our last publication on Pharmacological Research entitled "Nanoparticles Encapsulating Phosphatidylinositol Derivatives Promote Neuroprotection and Functional Improvement via a long-lasting activation of TRPML1 lysosomal channel in Preclinical Models of ALS" Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease currently incurable, in which motor neuron degeneration leads to voluntary skeletal muscle atrophy. Self-assembled nanoparticles releasing PI(3,5)P2 may prolong ALS animal survival and reduce ALS motor symptoms. These nanoparticles can be used to co-deliver RNAs for combined therapies against ALS. Thank you to the team of prof. Agnese Secondo and all the other collegues for the stimulating collaboration. #ALS #Amyotrophiclateralsclerosis #lipidnanoparticles #selfassemblingnanoparticles #LNP #SANP #lysosomaldisfunction #TRPLM1 #neurodegenerativedisease https://lnkd.in/dDRgCXnw